Scott S. Tykodi
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Scott S. Tykodi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:37 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03260504 · Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerUniversity of Washington · terminated · Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting Novel T Cell Antigens on Renal Cell CarcinomaK08CA121912 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2006 to 2010 · $134,460 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:37 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med · 20126,565 citationsRCR 174.5
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med · 20154,774 citationsRCR 147.0
- 654 citationsRCR 22.3
- 269 citationsRCR 10.1
- 208 citationsRCR 5.8
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).Cancer Discov · 2020204 citationsRCR 7.3
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.J Immunother Cancer · 2020197 citationsRCR 7.5
- 152 citationsRCR 4.1
- Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.J Immunother Cancer · 2022130 citationsRCR 8.6
- Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.J Clin Oncol · 2021114 citationsRCR 5.7